ELELYSOTM (taliglucerase alfa) has received kosher certification
What does kosher certification mean?
The word kosher means proper or acceptable. Certified kosher products are prepared in accordance with kosher laws that have their origin in the Bible, which lists the basic categories of food items that are not kosher.
For ELELYSO, this means that the ingredients and processes used to manufacture the medicine adhere to these laws and traditions. This certification does not change the way ELELYSO is made or what goes into it. While kosher certification is not necessary for life-saving treatments, or those not administered orally, it shows Pfizer's commitment to the Gaucher disease community. Gaucher disease affects 1 in 600 people of Ashkenazi Jewish heritage.
In short, ELELYSO for patients with adult type 1 Gaucher disease is now the first prescription medication to receive kosher certification from the Orthodox Union.
For more information
- To find out about how ELELYSO is made by the Israeli company Protalix, please see our manufacturing video.
- To learn more about kosher certification, please visit the Orthodox Union.
- For more information about the Israeli company that manufactures ELELYSO, please visit Protalix.
For questions, please contact Mariah Kelly, RN, Patient Affairs Liaison.
Before proceeding to ELELYSO.com please scroll to review Important Safety Information and Indication. Click the X in the upper right-hand corner to close this box.
IMPORTANT SAFETY INFORMATION
As with any intravenous protein medicine, like enzyme replacement therapy (ERT), severe allergic reactions (including anaphylaxis) have been observed in patients treated with ELELYSO. If this occurs, ELELYSO should be immediately discontinued, and appropriate medical treatment should be initiated. Patients who have experienced anaphylaxis to ELELYSO or another ERT should proceed with caution upon retreatment.
In addition, infusion reactions (including allergic reactions)—defined as a reaction occurring within 24 hours of the infusion—were the most commonly observed reactions to ELELYSO. The most commonly observed infusion reactions were headache, chest pain or discomfort, weakness, fatigue, hives, abnormal redness of the skin, increased blood pressure, back or joint pain, and flushing. Other infusion or allergic reactions included swelling of the face, mouth, and/or throat; wheezing; shortness of breath; skin color turning blue; coughing; and low blood pressure. Most of these reactions were mild and did not require treatment.
Management of infusion reactions is based on the type and severity of the reaction. Your doctor may manage infusion reactions by temporarily stopping the infusion, slowing the infusion rate, or treating with medications such as an antihistamine and/or a fever reducer. Treatment with antihistamines and/or corticosteroids prior to infusion with ELELYSO may prevent these reactions.
Other common adverse reactions observed were upper respiratory tract infections, throat infection, flu, urinary tract infection, and pain in extremities.
As with all therapeutic proteins, including ERTs, there is a possibility of developing antibodies to ELELYSO. However, it is currently unclear whether this has an impact on the clinical response or adverse reactions. Patients with an immune response to other ERTs who are switching to ELELYSO should continue to be monitored for antibodies. Comparison of the frequency of antibodies across ERTs may be misleading. Patients who have developed infusion or immune reactions with ELELYSO or with another ERT should be monitored for antidrug antibodies when being treated with ELELYSO.
If you are pregnant, or plan to become pregnant, you should talk to your doctor about potential benefits and risks.
ELELYSO™ (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.